Literature DB >> 2543582

Ligand-specific and non-specific in vivo modulation of human epidermal cellular retinoic acid binding protein (CRABP).

S Hirschel-Scholz1, G Siegenthaler, J H Saurat.   

Abstract

Retinoic acid (RA) is bound intracellularly by a specific, low molecular weight protein (CRABP), that is unrelated to its nuclear receptor and whose function and regulation are still unknown. In the present study we were able to obtain an in vivo modulation of CRABP by different stimuli in one of the major target organs of RA: the human skin. We found increased CRABP after daily application during 4 days of natural or synthetic retinoids (RA, acitretin, isotretinoin, Ro137410, retinol), that have either a high affinity to CRABP or can be transformed into RA. Only Ro150778 with no affinity and no reported transformation had no effect. No macro- or microscopical changes could be observed with any of the tested compounds. Induction of inflammatory and hyperproliferative changes in the skin by topical dithranol treatment, UVB irradiation or scotch tape stripping also induced a significant increase of CRABP 3 days after exposure. Topical diflucortolone showed not only a tendancy to decrease intrinsic CRABP levels, but significantly reduced the retinoid stimulated rise of CRABP. Thus we conclude that the increase of CRABP in a fully differentiated adult tissue seems to be a biological phenomenon following processes of inflammation and proliferation with a lag of several days, while retinoids seem to be able to induce such a rise independently of, or before, the appearance of such processes. Corticosteroids seem to be inhibitors of this reaction. We discuss the hypothesis that CRABP might function as an intracellular 'buffer' in the case of RA overload.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543582     DOI: 10.1111/j.1365-2362.1989.tb00221.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  5 in total

1.  Topical all-trans retinoic acid (RA) induces an early, coordinated increase in RA-inducible skin-specific gene/psoriasin and cellular RA-binding protein II mRNA levels which precedes skin erythema.

Authors:  C C Zouboulis; J J Voorhees; C E Orfanos; A Tavakkol
Journal:  Arch Dermatol Res       Date:  1996-10       Impact factor: 3.017

2.  All-trans-retinoic acid: a phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma.

Authors:  S Phuphanich; C Scott; A J Fischbach; C Langer; W K Yung
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

Review 3.  Clinical pharmacokinetics of tretinoin.

Authors:  M B Regazzi; I Iacona; C Gervasutti; M Lazzarino; S Toma
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

4.  Quantitation of human cellular retinoic acid-binding protein II (CRABP-II) RNA from cultured human skin fibroblast cells and human skin biopsies treated with retinoic acid.

Authors:  L Zhou; G Otulakowski; J Pang; D G Munroe; R J Capetola; C Lau
Journal:  Nucleic Acids Res       Date:  1992-12-11       Impact factor: 16.971

5.  Acitretin : A Review of its Pharmacology and Therapeutic Use.

Authors:  Tania Pilkington; Rex N Brogden
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.